Cargando…

Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer

Breast cancer is a persistent threat to women worldwide. A large proportion of breast cancers are dependent on the estrogen receptor α (ERα) for tumor progression. Therefore, targeting ERα with antagonists, such as tamoxifen, or estrogen deprivation by aromatase inhibitors remain standard therapies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hany, Dina, Zoetemelk, Marloes, Bhattacharya, Kaushik, Nowak-Sliwinska, Patrycja, Picard, Didier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032341/ https://www.ncbi.nlm.nih.gov/pubmed/36869202 http://dx.doi.org/10.1007/s00018-023-04730-x

Ejemplares similares

Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma
por: Zoetemelk, Marloes, et al.
Publicado: (2019)

Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment
por: Zoetemelk, Marloes, et al.
Publicado: (2020)

Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer
por: Vafeiadou, Vasiliki, et al.
Publicado: (2022)

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance
por: Rausch, Magdalena, et al.
Publicado: (2020)

CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen receptor α activity and tamoxifen resistance of breast cancer cells
por: Hany, Dina, et al.
Publicado: (2023)

Carvacrol: An In Silico Approach of a Candidate Drug on HER2, PI3Kα, mTOR, hER-α, PR, and EGFR Receptors in the Breast Cancer
por: Herrera-Calderon, Oscar, et al.
Publicado: (2020)

ERα activity depends on interaction and target site corecruitment with phosphorylated CREB1
por: Berto, Melissa, et al.
Publicado: (2018)

Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering
por: Weiss, Andrea, et al.
Publicado: (2019)

Cystatin SN Affects Cell Proliferation by Regulating the ERα/PI3K/AKT/ERα Loopback Pathway in Breast Cancer
por: Liu, Yanfang, et al.
Publicado: (2019)

Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma
por: Rausch, Magdalena, et al.
Publicado: (2020)

Expression of ERβ, ERα and Her-2 and distribution of molecular subtypes in Uygur and Han patients with breast cancer
por: GUO, LIYING, et al.
Publicado: (2014)

Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ERα and HER2/neu
por: Scherbakov, A. M., et al.
Publicado: (2015)

Resveratrol fuels HER2 and ERα-positive breast cancer behaving as proteasome inhibitor
por: Andreani, Cristina, et al.
Publicado: (2017)

Deciphering of a Putative GPER Recognition Domain in ERα and ERα36
por: Acramel, Alexandre, et al.
Publicado: (2022)

Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
por: Mishra, Anjali, et al.
Publicado: (2020)

Cooperative interaction between ERα and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis
por: Mohammadi Ghahhari, Nastaran, et al.
Publicado: (2022)

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer
por: Fox, Emily M., et al.
Publicado: (2012)

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
por: Buckbinder, Leonard, et al.
Publicado: (2023)

Super-enhancer-controlled positive feedback loop BRD4/ERα–RET–ERα promotes ERα-positive breast cancer
por: Zheng, Zao-zao, et al.
Publicado: (2022)

YAP inhibits ERα and ER(+) breast cancer growth by disrupting a TEAD-ERα signaling axis
por: Li, Xu, et al.
Publicado: (2022)

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
por: Lin, Sheng-Li, et al.
Publicado: (2010)

Prevention of Obesity and Insulin Resistance by Estrogens Requires ERα Activation Function-2 (ERαAF-2), Whereas ERαAF-1 Is Dispensable
por: Handgraaf, Sandra, et al.
Publicado: (2013)

Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer
por: Li, Yuanyuan, et al.
Publicado: (2013)

Novel nano-pomegranates based on astragalus polysaccharides for targeting ERα-positive breast cancer and multidrug resistance
por: Wang, Bingjie, et al.
Publicado: (2020)

Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer
por: Ni, Wenting, et al.
Publicado: (2021)

HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation
por: Park, B-W, et al.
Publicado: (2005)

Human estrogen receptor-α (ER-α) transactivation by selective estrogen receptor modulators (SERMs) on VIT regulatory region in ER-α-negative breast cancer cell line Evsa-T transiently transfected by ER-α
por: Nyamagana Butera, IP, et al.
Publicado: (2001)

The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
por: Rokicki, Jerzy, et al.
Publicado: (2010)

Concomitant high expression of ERα36, EGFR and HER2 is associated with aggressive behaviors of papillary thyroid carcinomas
por: Dai, Yu-Jie, et al.
Publicado: (2017)

Influence of Cellular ERα/ERβ Ratio on the ERα-Agonist Induced Proliferation of Human T47D Breast Cancer Cells
por: Covaleda, Ana M. Sotoca, et al.
Publicado: (2008)

The Hsp70–Hsp90 go-between Hop/Stip1/Sti1 is a proteostatic switch and may be a drug target in cancer and neurodegeneration
por: Bhattacharya, Kaushik, et al.
Publicado: (2021)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Genomics of Signaling Crosstalk of Estrogen Receptor α in Breast Cancer Cells
por: Dudek, Peter, et al.
Publicado: (2008)

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets
por: Gates, Leah A., et al.
Publicado: (2018)

Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer
por: Su, Peng, et al.
Publicado: (2014)

Respective role of membrane and nuclear estrogen receptor (ER) α in the mandible of growing mice: Implications for ERα modulation
por: Vinel, Alexia, et al.
Publicado: (2018)

Translational reprogramming in response to accumulating stressors ensures critical threshold levels of Hsp90 for mammalian life
por: Bhattacharya, Kaushik, et al.
Publicado: (2022)

ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway
por: Zhu, Linlin, et al.
Publicado: (2018)

Characterizing the selectivity of ER α-glucosidase inhibitors
por: O’Keefe, Sarah, et al.
Publicado: (2019)

Expression of oestrogen receptors, ERα, ERβ, and ERβ variants, in endometrial cancers and evidence that prostaglandin F may play a role in regulating expression of ERα
por: Collins, Frances, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_p4qamshlo7ulrlu1550tr8nt08